1. Graft-versus-host disease propagation depends on increased intestinal epithelial tight junction permeability
- Author
-
Nalle, Sam C., Zuo, Li, Ong, Ma. Lora Drizella M., Singh, Gurminder, Worthylake, Alicia M., Choi, Wangsun, Manresa, Mario Cabrero, Southworth, Anna P., Edelblum, Karen L., Baker, Gregory J., Joseph, Nora E., Savage, Peter A., and Turner, Jerrold R.
- Subjects
Apoptosis -- Research ,Graft vs. host disease -- Care and treatment -- Prevention ,Hematopoietic stem cell transplantation -- Usage ,T cells -- Research ,Enzymes ,Histochemistry ,Permeability ,Stem cells ,Surgery ,Stem cell transplantation ,Health care industry - Abstract
Graft-versus-host disease (GVHD) is a complication of hematopoietic stem cell transplantation (HSCT) that affects multiple organs. GVHD-associated intestinal damage can be separated into two distinct phases, initiation and propagation, which correspond to conditioning-induced damage and effector T cell activation and infiltration, respectively. Substantial evidence indicates that intestinal damage induced by pretransplant conditioning is a key driver of GVHD initiation. Here, we aimed to determine the impact of dysregulated intestinal permeability on the subsequent GVHD propagation phase. The initiation phase of GVHD was unchanged in mice lacking long MLCK (MLCK210), an established regulator of epithelial tight junction permeability. However, MLCK210-deficient mice were protected from sustained barrier loss and exhibited limited GVHD propagation, as indicated by reduced histopathology, fewer [CD8.sup.+] effector T cells in the gut, and improved overall survival. Consistent with these findings, intestinal epithelial MLCK210 expression and enzymatic activity were similarly increased in human and mouse GVHD biopsies. Intestinal epithelial barrier loss mediated by MLCK210 is therefore a key driver of the GVHD propagation. These data suggest that inhibition of MLCK210-dependent barrier regulation may be an effective approach to limiting GVHD progression., Introduction Allogeneic hematopoietic stem cell transplantation (HSCT) is used in the treatment of neoplastic and immune disorders. Graft-versus-host disease (GVHD), in which donor-derived T cells target recipient alloantigens to cause [...]
- Published
- 2019
- Full Text
- View/download PDF